Atea Pharmaceuticals (AVIR) Change in Acquisitions & Divestments (2022 - 2026)

Atea Pharmaceuticals' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $104.3 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 49.92% year-over-year to $104.3 million; the TTM figure through Mar 2026 stood at $366.8 million (down 26.87% YoY), while the FY2025 annual figure was $470.7 million, down 9.0% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $104.3 million, up from $90.4 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $224.0 million in Q1 2024, with the low at $55.1 million in Q4 2024.
• The 5-year median for Change in Acquisitions & Divestments is $111.1 million (2024), against an average of $127.6 million.
• The sharpest annual moves came in 2025 and 2026: Change in Acquisitions & Divestments surged 64.02% in 2025, then tumbled 49.92% in 2026.
• Atea Pharmaceuticals' Change in Acquisitions & Divestments stood at $91.9 million in 2022, then retreated by 18.38% to $75.0 million in 2023, then declined by 26.53% to $55.1 million in 2024, then soared by 64.02% to $90.4 million in 2025, then climbed by 15.38% to $104.3 million in 2026.
• Business Quant data shows AVIR's Change in Acquisitions & Divestments at $104.3 million in Q1 2026, $90.4 million in Q4 2025, and $56.1 million in Q3 2025.